Business
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied anti
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical use","length":129,"tagName":"p","attribs":{}},{"type":"text","content":"LAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied antibiotic for this use.","length":561,"tagName":"p"},{"type":"text","content":"Dan Wu, Ph.D., Senior Director, Pharmaceutical Sciences & Technology, Bausch Health, and a member of the development team behind ARESTIN, reflected, "The 'why' behind developing ARESTIN began with recognizing that periodontal disease is a localized, chronic bacterial condition and that clinicians had no targeted way to help address it. There was a gap in treatment, and ARESTIN was developed to help fill that need by delivering antibiotic therapy directly into the periodontal pocket, using tiny microspheres that release the antibiotic gradually over time before naturally biodegrading."","length":613,"tagName":"p"},{"type":"text","content":"Periodontal disease remains one of the most prevalent chronic oral health conditions globally, affecting more than one billion people1. As part of comprehensive periodontal disease management, many dental professionals have incorporated ARESTIN with scaling and root planing (SRP).","length":281,"tagName":"p"},{"type":"text","content":""Reaching Arestin's 25-year milestone as the only FDA-approved locally applied antibiotic reflects our commitment to periodontal care," said Tom Stern, Vice President and General Manager of the OraPharma business, Bausch Health's dentistry division. "As we recognize this legacy, we are equally focused on the future—one defined by innovation and deeper collaboration with the dental community. Building on Arestin's impactful history, we continue to support non-surgical periodontal treatment for appropriate patient...